HER2-negative breast cancer
Oncology · 2023–2024
2decisions
1medicine
2carried consumer input
13individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| olaparib Treatment of HER2-negative metastatic breast cancer in patients with a confirmed germline BRCA1 or BRCA2 mutation who have received prior chemotherapy in the… | Jul 2024 | Recommended with restriction | input received |
| olaparib Adjuvant treatment of human epidermal growth factor 2 negative (HER2-) high-risk early breast cancer with a confirmed germline BRCA1 or BRCA2 mutation who have… | Mar 2023 | Not recommended | 13 individuals Medical Oncology Group · Breast Cancer Network Australia · Rare Cancers Australia |
Who spoke
Medical Oncology Group · Breast Cancer Network Australia · Rare Cancers Australia
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 2 of 2 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.